The potentially severe side effects of systemic corticosteroids and immunosuppressants used in Pemphigus vulgaris (PV) call for novel therapeutic approaches. In this context, pharmacological inhibition of major pathogenic signalling effectors represents a promising alternative. However, we have also shown that overinhibition of effectors required for epidermal homeostasis can exacerbate PV pathophysiology implicating transepidermal keratinocyte fragility. A feedforward target validation therefore preferentially includes studies on knockout mouse models. We previously reported on successful amelioration of PV blisters following inhibition of non-apoptotic, low-level caspase-3. Here, we use conditional, keratinocyte-specific caspase-3-deficient 
| BACKGROUND
Pemphigus vulgaris (PV) is a severe autoimmune disease characterized by suprabasilar blisters in the epidermis and mucous membranes, and also in hair follicles (HF). [1, 2] In the majority of patients, pathogenic autoantibodies target the desmosomal cadherin desmoglein 3 (Dsg3) or Dsg3/Dsg1, resulting in mucosal/HF or mucosal/HF/epidermal blisters, respectively, following desmosome reduction. PV patients are commonly treated with systemic corticosteroids and immunosuppressants. Although B-cell depletion has recently emerged as an effective treatment in pemphigus, the potentially severe side effects related to standard therapies call for additional therapeutic approaches. [1] Our current understanding is that PV antibodies primarily target extradesmosomal, Triton X-100 soluble, Dsg3 proteins, disrupting their transadhesion and triggering a pathogenic signalling response that affects keratinocytes' adhesive properties and strength. [1, 3] Reduced blistering occurs upon pretreatment of PV antibody-injected mice with pharmacological inhibitors of p38MAPK, EGFR and c-Myc. [4] [5] [6] These findings have paved the way for the development of novel therapies in PV. However, it has also been observed that overinhibition of some signalling molecules required for epidermal homeostasis, such as EGFR, increased rather than decreased acantholysis in presence of PV antibodies. [4] Some studies have also shown that the passive transfer of PV antibodies into mice, which are deficient for the pharmacological target of interest represents a feedforward approach to address whether (i) potential high-dose inhibition can limit clinical translation due to keratinocyte fragility and (ii) a specific inhibitor is safe for PV clinical trials. [4, 7] 
| QUESTIONS ADDRESSED
Caspase-3 is one of the major effectors of apoptotic cell death. In recent years, several authors have further described non-apoptotic, lowlevel caspase-3 activation in different cellular systems. [8] We reported an early transient activation of non-apoptotic, low-level caspase-3 in PV, as well as reduced pathogenic signalling and blistering upon treatment of mice with caspase-3 inhibitors prior to injection of PVIgG or the most potent pathogenic monoclonal anti-Dsg3 antibody AK23. [1, 9] Here, we sought to substantiate the feasibility of caspase-3 inhibitors in PV using keratinocyte-specific caspase-deficient mice.
| EXPERIMENTAL DESIGN
We applied the adult PV mouse model [10] to conditional K14 promoterdriven keratinocyte-specific caspase-3-deficient mice (casp3 EKO ) ( Fig.   S1A ; Appendix S1). In the adult PV mouse model, characteristic blisters develop in response to AK23 in the stem cell niche (bulge) of resting telogen hair follicles (HFs) concurrently with increased proliferation. Furthermore, as in PV patients with Dsg3 antibodies, [10] blisters occur in mucous membranes such as the oral cavity while the epidermis remains intact. [11] All experiments were approved by the ethics committee, Canton Bern, Switzerland (BE2/15).
| RESULTS
Nine-week-old wild-type (+/+; n = 4), heterozygous (+/−; n = 6) and casp3 EKO mice (−/−; n = 7) were subcutaneously injected with 12.5 μg/g body weight of the pathogenic Dsg3 antibody AK23, or control non-specific mouse IgG (mIgG) ((+/+; (n = 5); casp3 EKO (n = 2)).
After 24 hours, weight loss, a sensitive read-out for oral blisters, was least severe in AK23-injected casp3 EKO mice compared to heterozy- (Fig. S1C) . Furthermore, no epidermal fragility was observed upon AK23 injection in casp3 EKO mice ( Figure 1A ). As expected, AK23 but not mIgG induced PV blisters in the bulge of telogen HFs. [9, 10] The number of blistered HFs (n > 100 total HFs analysed per animal) was similar in wild-type and heterozygous mice with 77.3 ± 5.3% and 78.4 ± 5.6% HF blisters, respectively.
However, blistering was reduced to 30.6 ± 5.5% in casp3 EKO telogen HFs ( Figure 1A ) and hair loss diminished as assessed by semiquantitative tape stripping (Fig. S1D) . We next examined the consequences of caspase-3 deletion on proliferation, a downstream event observed in the epidermis and HFs of PV mouse models and PV patients. [5, 10] Injection of AK23 resulted in significantly increased proliferation by means of Ki67-positive nuclei in the HF bulge of wild-type and heterozygous mice, but not of casp3 EKO animals ( Figure 1B ).
We further investigated PV-relevant, caspase-3-dependent processes such as Dsg3 cleavage, which has been involved in proteolytic shedding of Dsg3 and adhesive reshuffling, and p38MAPK activation. [4] In line with our previous findings, analysis of Triton X-100 soluble skin extracts showed higher full-length Dsg3 levels in all AK23-treated mice ( Figure 1C, immunoblot) . [9, 10] Unlike AK23-injected wild-type and heterozygous animals, the 100 kDa membrane-anchored, cleaved Dsg3 was, however, not significantly increased in casp3 EKO mice compared to mIgG controls. Furthermore, the ratio of phosphorylated (P)-p38/p38 was significantly reduced in the casp3 EKO mice compared to mIgG-and AK23-treated wild-type and heterozygous mice ( Figure 1C ).
In casp3 EKO mice, pro-caspase-3 was weakly detectable. As complete deletion of the caspase-3 gene was confirmed by toe genotyping (Fig.   S1A ), the caspase-3 protein likely stems from fibroblasts in the skin extracts. Taken together, our new findings are in agreement with our previous studies using caspase-3 inhibitors in our PV mouse model. [9] 
| CONCLUSIONS
Our current results corroborate the involvement of caspase-3 in PV pathophysiology and place this protease upstream of acantholysis and proliferation as well as p38MAPK. Furthermore, caspase-3 inhibitors prevented acantholysis both in response to AK23 and PVIgG, [9] and keratinocyte fragility was absent in AK23-injected casp3 EKO mice. These collective results provide proof of principle that caspase-3 is an eligible, feasible and safe therapeutic target in PV.
Moreover, caspase inhibitors, such as the well-tolerated IDN-6556, F I G U R E 1 Epidermal-specific caspase-3 ablation (Fig. S1A) counterstained with Hoechst 33258 (blue). Ki67-positive cells in the HF bulge are indicated with arrowheads. Scale bar = 20 μm. C, Representative immunoblots and graphs for indicated proteins of Triton X-100 soluble skin extracts from mIgG-treated wild-type (+/+; n = 5) and AK23-treated wild-type ((+/+; n = 4), heterozygous (+/−; n = 6) and casp3 EKO (−/−; n = 7) skin at 24 h (numbers indicate different animals). Signals were quantified and normalized to tubulin, and the mean ± SEM is plotted relative to the average of animals injected with mIgG set to 1. One representative PVDF membrane is shown of three required to analyse all protein samples. The tubulin blot is from Dsg3 and p38MAPK analyses. Note that at 24 h full-length Dsg3 levels are increased in the Triton X-100 fraction, as reported previously. [10] Low levels of pro-caspase-3 detected in casp3 EKO mice likely stem from fibroblasts present in the skin extracts. Data are mean ± SEM. *P ≤ .05, **P ≤ .01 and ***P ≤ .001. PV, pemphigus vulgaris; AK23, mouse monoclonal pathogenic anti-Dsg3 antibody; mIgG, non-specific mouse IgG; HF, hair follicle; Bu, bulge are in phase II clinical trials for other indications. [12] However, in line with our report using caspase-3 inhibitors, [9] blistering was not completely prevented in absence of caspase-3. This supports the involvement of other effectors in the acantholytic process. Collectively, our results now justify the assessment of caspase-3 inhibitors in PV clinical trials and further suggest that a combined therapy with low dose inhibitors acting on other effectors in the acantholytic process, such as EGFR or p38MAPK, either up-or downstream of caspase-3, might also be efficacious and more tolerable.
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